Italia markets close in 5 hours 36 minutes

Gilead Sciences, Inc. (GIS.DE)

XETRA - XETRA Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
62,51-0,43 (-0,68%)
In data: 09:46AM CEST. Mercato aperto.
Schermo intero
Chiusura precedente62,94
Aperto62,59
Denaro62,32 x 25500
Lettera62,68 x 20000
Min-Max giorno62,51 - 62,68
Intervallo di 52 settimane61,77 - 80,00
Volume187
Media Volume982
Capitalizzazione77,948B
Beta (5 anni mensile)0,20
Rapporto PE (ttm)14,81
EPS (ttm)4,22
Prossima data utili25 apr 2024
Rendimento e dividendo (futuro)2,85 (4,53%)
Data ex dividendo14 mar 2024
Stima target 1AN/D
  • GlobeNewswire

    Global CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032

    PALM BEACH, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell therapy medicines. The CAR T-cell therapy market is currently going through a rapid expansion, owing to rapidly expanding clinical trial activities and recent commercialization of CAR-T cell therapy, whic

  • GlobeNewswire

    Center for Disease Analysis Foundation Announces Receipt of an $8 Million Grant from Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States

    LAFAYETTE, Colo., July 20, 2023 (GLOBE NEWSWIRE) -- The Center for Disease Analysis Foundation (CDA Foundation) announced today that it received an $8 million grant from Gilead Sciences (Nasdaq: GILD) as part of Gilead’s Relink grant program. CDA Foundation will disperse the grant to qualifying tax-exempt organizations to contact diagnosed but untreated patients with hepatitis C virus (HCV) or hepatitis B virus (HBV) infection to bring them back into care. Despite the availability of existing tr